SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) between January 19 , 202 6 and March 24 , 202 6 , inclusive. Should You Join The ImmunityBio Class Action Lawsuit?

GlobeNewsWire • 8 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).   Such investors are advised to contact Danielle Peyton at  [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

GlobeNewsWire • 2 hours ago

Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors

LOS ANGELES, May 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors that bought securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). Immunity Bio investors have until May 26, 2026 to file a lead plaintiff motion.

GlobeNewsWire • 9 hours ago

Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

NEW YORK, May 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

PRNewsWire • 9 hours ago

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, May 12, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). IF YOU SUFFERED A LOSS ON YOUR IMMUNITYBIO INVESTMENTS, CLICK  HERE BEFORE MAY 26, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?

PRNewsWire • 2 hours ago

IBRX 2-WEEK DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman

SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio's lead biologic product (Anktiva), which the FDA said were misleading efficacy claims.

GlobeNewsWire • 2 hours ago

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - May 12, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period").

Newsfile Corp • 6 hours ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

New York, New York--(Newsfile Corp. - May 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ImmunityBio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • an hour ago

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, May 11, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 19, 2026, and March 24, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before May 26, 2026.

GlobeNewsWire • May 11, 2026

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Concealed Drug Limitation Risks: Levi & Korsinsky

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that a securities class action has been filed against ImmunityBio, Inc. (NASDAQ: IBRX). YOU MAY BE AFFECTED IF YOU: Purchased IBRX stock between January 19, 2026 and March 24, 2026 Lost money on your ImmunityBio investment Submit your information to recover losses or contact Joseph E.

GlobeNewsWire • May 11, 2026